ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
0.174 ^USD	+4.57%		-0.57%	-30.32%

May. 15	Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M	MT
Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ

ReShape Lifesciences Inc. Announces Resignation of Scott P. Youngstrom as Senior Vice President, Finance and Chief Financial Officer, Effective October 1, 2019

August 06, 2019 at 04:23 pm EDT

ReShape Lifesciences Inc. announced that Scott P. Youngstrom, Senior Vice President, Finance and Chief Financial Officer provided the Company with notice of his resignation on August 1, 2019, effective October 1, 2019.

Latest news about ReShape Lifesciences Inc.

Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M	May. 15	MT
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Certain Restricted Stock Units of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Warrants of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Options of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Common Stock of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	Mar. 28	MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	Mar. 28	CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	Feb. 22	CI
Top Midday Gainers	Dec. 13	MT
North American Morning Briefing : Traders Await FOMC, Powell	Dec. 13	DJ
ReShape Lifesciences Gets FDA Approval for PMA Supplement Used in Latest Lap-Band	Dec. 12	DJ
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX	Dec. 12	CI
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023	Nov. 09	CI
Transcript : ReShape Lifesciences Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M	Nov. 08	MT
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-29	MT
Sector Update: Health Care Stocks Declining Friday Afternoon	23-09-29	MT
ReShape Lifesciences Prices $3 Million Offering at $0.33 Per Unit	23-09-29	MT
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System	23-09-21	CI
ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device	23-09-14	CI
Transcript : ReShape Lifesciences Inc., Q2 2023 Earnings Call, Aug 07, 2023	23-08-07

Chart ReShape Lifesciences Inc.

Duration

Period

More charts

Company Profile

ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

Sector

Advanced Medical Equipment & Technology

Calendar

May. 15 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for ReShape Lifesciences Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.174 USD

Average target price

1 USD

Spread / Average Target

+474.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
RESHAPE LIFESCIENCES INC.	-30.32%	4.08M
THERMO FISHER SCIENTIFIC	+12.85%	229B
DANAHER CORPORATION	+13.88%	195B
INTUITIVE SURGICAL, INC.	+18.39%	142B
BOSTON SCIENTIFIC CORPORATION	+28.78%	109B
SIEMENS HEALTHINEERS AG	+1.63%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+18.24%	54.33B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	52.09B
AGILENT TECHNOLOGIES, INC.	+10.83%	45.15B
GE HEALTHCARE TECHNOLOGIES INC.	+5.94%	37.39B

Other Advanced Medical Equipment & Technology